Navigation Links
AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
Date:6/17/2013

nt activity was observed in the trial and warrants further single-agent and combination trials evaluating ABT-199/GDC-0199 in patients with CLL. Dose and schedule evaluation will continue.

Of the 56 patients enrolled, 34 were considered high-risk CLL patients – those with deletions of chromosome 17p or whose disease is refractory to fludarabine therapy. In the post-hoc analysis to determine if high-risk CLL patients could have similar response rates to the overall study population, 17 (30%) patients had 17p deletion and 18 (32%) had fludarabine-refractory CLL.

"High-risk CLL patients are a challenging subgroup to treat, as they tend to have disappointing results with conventional chemotherapy regimens," said Professor Andrew Roberts, Hematologist at the Royal Melbourne Hospital and head of Clinical Translation at the Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia.  "While still early in the development process, preliminary response rates observed in these patients appear similar to those observed in other CLL patients being treated with ABT-199/GDC-0199.  These data justify further investigation of this compound in patients with 17p deletion and fludarabine-refractory CLL."

During the study, 16 patients discontinued treatment; nine due to progressed disease and seven for other reasons (two due to TLS, three for other illnesses, one for thromboembolic event and one consent withdrawal). The most common hematological adverse events (AEs) during the study were neutropenia (39%), thrombocytopenia (18%) and anemia (13%). The most common non-hematological AEs were diarrhea (41%), nausea (38%), fatigue (29%), upper respiratory tract infection (27%) and cough (23%). In the first study group, TLS occurred in all three of the enrolled patients; once the modified dosing schedule was utilized, three of the 53 patients experienced TLS, one of which was a fatal
'/>"/>

SOURCE AbbVie
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. AbbVie Named to S&P 500 Dividend Aristocrat Index
2. AbbVie Issues Inaugural Full-Year Outlook for 2013
3. AbbVie to Present at Barclays Global Health Care Conference
4. Receptos Licenses Anti-Interleukin-13 Antibody from AbbVie for Phase 2 Development in Orphan Disease
5. AbbVie to Host First-Quarter Earnings Conference Call
6. AbbVie Reports First-Quarter 2013 Financial Results
7. AbbVie CF Scholarship Application Now Available for Exceptional Undergraduate and Graduate Students with Cystic Fibrosis
8. AbbVies Investigational HCV Regimen Receives Breakthrough Therapy Designation from the U.S. Food and Drug Administration
9. AbbVie to Present at Bank of America Merrill Lynch 2013 Health Care Conference
10. AbbVie and Alvine to Collaborate on Investigational Oral Therapy for Celiac Disease
11. AbbVie to Present Data on Investigational Anti-Cancer Compounds at American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Aug. 28, 2015  Today, in final recognition of ... Lens Health Week, 1-800 Contacts is sharing how to ... contact lens wearers who do not properly care for ... eye infections. Most contact lens wearers ... a clean lens case is sometimes overlooked.  When proper ...
(Date:8/28/2015)... Aug. 28, 2015 ... the addition of the "Investigation Report on ... offering. Developed by Pharmacia & Upjohn ... agonist which effectively reduces intraocular pressure. As the ... (under the trade name of Xalatan) entered ...
(Date:8/28/2015)... 2015 Perrigo Company plc ("Perrigo") (NYSE: ... ("Mylan") (NASDAQ: MYL ) shareholder vote regarding its ... views of Mylan,s offer to Perrigo shareholders have always ... Board,s careful reflection of the value available to Perrigo ... that Mylan has allowed its shareholders to consider," said ...
Breaking Medicine Technology:1-800 Contacts Shares Tips on How to Clean Lens Cases 2China Latanoprost Market Investigation Report 2015-2019 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5
... WELLESLEY HILLS, Mass., Aug. 25 Joseph F. ... Spherics, Inc. ("Spherics") for,the benefit of creditors, announced ... at a sealed bid auction on October 10,2008., ... Levodopa-Carbidopa that,is the current gold standard treatment for ...
... Development Studies ... Planned, COPENHAGEN, ... ofatumumab in chronic lymphocytic,leukemia and non-Hodgkin,s lymphoma., Genmab A/S (OMX: GEN) ... (CLL) and follicular,non-Hodgkin,s lymphoma (NHL) this year., "Genmab and GSK have ...
Cached Medicine Technology:Spherics, Inc. Offers Extended Release Formulation for Sustained and Stable Levodopa Levels 2Genmab Announces Upcoming Ofatumumab Studies 2Genmab Announces Upcoming Ofatumumab Studies 3Genmab Announces Upcoming Ofatumumab Studies 4
(Date:8/30/2015)... ... August 30, 2015 , ... SonaCare ... for the treatment of prostate cancer, has announced the roll-out of its newest ... treatment center in Puerto Vallarta, Mexico. , The Sonablate® technology currently in use ...
(Date:8/29/2015)... ... August 29, 2015 , ... On Saturday, September 19, 2015, ... Research Foundation (Meso Foundation) will present an educational program titled “Asbestos and Your ... lasts through 9:30 PM (doors open at 6:45pm) at Calvary United Methodist Church, 16 ...
(Date:8/29/2015)... ... August 29, 2015 , ... Dr. Tim Novelli, DC., Founder ... mission is to increase acceptance of the chiropractic field in the military. All too ... them. Although Chiropractic was made available to the VA program over a decade ...
(Date:8/29/2015)... , ... August 29, 2015 , ... ... angina, chronic obstructive pulmonary disease (including emphysema), or asthma, are at higher risk ... angina, previous heart attack, heart failure or heart-rhythm problems (arrhythmia or irregular heartbeat) ...
(Date:8/28/2015)... AZ (PRWEB) , ... August 29, 2015 , ... ... reinvent higher learning and the student experience as part of the EDUCAUSE - Next ... Gates Foundation . , This is the third Breakthrough Models Incubator hosted ...
Breaking Medicine News(10 mins):Health News:Image Fusion Technology Combines MRI and Ultrasound Images to Treat Prostate Cancer 2Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2Health News:Heart Fit Clinic Sounds the Alarm on Forest Fire Smoke and Chronic Heart Disease in Calgary Area 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 4
... the first time scientists have been able to film, ... and a DNA strand from an attacking virus. Researchers ... Scanning Atomic Force Microscope in Japan to produce amazing ... a virus trying to infect a bacterial host. ...
... commonly used measure for pain screening may only be modestly ... Medicine and the University of North Carolina. In a study ... General Internal Medicine, they evaluate the usefulness of a scale ... pain from 0 (no pain) to 10 (worst pain). ...
... next generation in medication therapy management ... and medication adherence ... a leading,developer of innovative clinical solutions that facilitate pharmacist-based,patient ... of the MirixaPro(TM) product suite (MirixaPro 2.2). With this,latest ...
... of the 62nd United Nations General Assembly Tomorrow, September ... ... dying,of hunger every day and governments failing to meet their millennium,commitment to halve ... and hunger to play a,central role "on the table" of the 62nd United ...
... often a key factor in the decision , MONDAY, Sept. ... deciding factor for men and women considering retirement, according to ... depression are more likely to retire early, while retirement-age women ... mild. , According to researchers at the University of Pennsylvania, ...
... Contrary to concerns that restricting work hours for surgical ... the residents education, a study in the September issue ... found that limiting work hours does not compromise education ... found that the new model improved overall teaching effectiveness ...
Cached Medicine News:Health News:Scientists reveal DNA-enzyme interaction with first ever real time footage 2Health News:Rating your pain from 0 to 10 might not help your doctor 2Health News:Mirixa Debuts New Clinical Technology Solutions for Enhancing Patient Care 2Health News:HungerFREE Campaign Tells UN: 'Put food on the table' 2Health News:Depression Pushes Middle-Aged Workers to Retire 2Health News:Study finds limiting work hours for surgical residents enhances training 2
... 6 is an enzyme immunoassay (EIA) test ... various specific nuclear antigens (SS-A, SS-B, RNP/Sm, ... is used as an aid in the ... connective tissue disease (MCTD), Sjgren's syndrome and ...
The 8500 is an extremely reliable portable pulse oximeter, requiring no periodic maintenance or calibration....
The PalmSAT® 2500 series are small, yet versatile digital pulse oximeters for accurate assessment of blood oxygen saturation and pulse rate. Choose alarm or non-alarm versions for your portable ...
The pocket-size Invacare Digit finger pulse oximeter is a convenient and economical solution to fast, reliable SpO2, pulse rate and pulse strength measurements. Its compact size is ideal for home use...
Medicine Products: